doxorubicin

You have access
Antitumor Activity of Symmetrical Selenoesters in Doxorubicin Resistant Breast Cancer
BALINT RACZ, ERZSEBET KRISTOF, ANNAMARIA KINCSES, ENRIQUE DOMINGUEZ-ALVAREZ and GABRIELLA SPENGLER

Anticancer Research November 2023, 43 (11) 4865-4872; DOI: https://doi.org/10.21873/anticanres.16683
Open Access
Elimination of Axillary-Lymph-Node Metastases in a Patient With Invasive Lobular Breast Cancer Treated by First-line Neo-adjuvant Chemotherapy Combined With Methionine Restriction
YUTARO KUBOTA, QINGHONG HAN, NORIYUKI MASAKI, CHIHIRO HOZUMI, KAZUYUKI HAMADA, YUSUKE AOKI, KOYA OBARA, TAKUYA TSUNODA and ROBERT M. HOFFMAN

Anticancer Research December 2022, 42 (12) 5819-5823; DOI: https://doi.org/10.21873/anticanres.16089
You have access
Effect of Chloroquine on Doxorubicin-induced Apoptosis in A549 Cells
KEISUKE SATO, NATSUKI OTA, SHOYA ENDO, AKIFUMI NAKATA, HIROSHI YAMASHITA and RYOSUKE TATSUNAMI

Anticancer Research August 2022, 42 (8) 4025-4035; DOI: https://doi.org/10.21873/anticanres.15899
You have access
Poly(Alkyloxyethylene-Lactate Phosphate) for Delivery of Doxorubicin: Synthesis and Characterization
KANJI YOSHIKAWA, TERUKI NII, KOLIO TROEV, KIMIKO MAKINO and ISSEI TAKEUCHI

Anticancer Research April 2022, 42 (4) 1801-1811; DOI: https://doi.org/10.21873/anticanres.15656
You have access
The Natural Estrogen Receptor Beta Agonist Silibinin as a Promising Therapeutic Tool in Diffuse Large B-cell Lymphoma
ELENA ORTONA, SILVIA L. LOCATELLI, MARIA TERESA PAGANO, BARBARA ASCIONE, GIUSEPPA CAREDDU, MARIA LUISA DUPUIS, MATTEO MARCONI, CARMELO CARLO-STELLA, WALTER MALORNI, PAOLA MATARRESE and MARINA PIERDOMINICI

Anticancer Research February 2022, 42 (2) 767-779; DOI: https://doi.org/10.21873/anticanres.15535
You have access
Differences in Transport Characteristics and Cytotoxicity of Epirubicin and Doxorubicin in HepG2 and A549 Cells
KATSUHITO NAGAI, SHUHEI FUKUNO, MAHO SHIOTA, MAYUKO TAMURA, SAYAKA YABUMOTO and HIROKI KONISHI

Anticancer Research December 2021, 41 (12) 6105-6112; DOI: https://doi.org/10.21873/anticanres.15430
You have access
Doxorubicin Combined With Ifosfamide for Sarcoma Induces Muscle Atrophy and Sleep Disruption
HIDEYUKI KINOSHITA, YOKO HAGIWARA, TAKESHI ISHII, HIROTO KAMODA, TOSHINORI TSUKANISHI, SEIJI OHTORI and TSUKASA YONEMOTO

Anticancer Research December 2021, 41 (12) 6273-6278; DOI: https://doi.org/10.21873/anticanres.15448
You have access
The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model
NATHANIEL F. WU, JUN YAMAMOTO, YUSUKE AOKI, NORIYUKI MASAKI, CARISSA SAMONTE, JUSTIN WU, MICHAEL BOUVET and ROBERT M. HOFFMAN

Anticancer Research October 2021, 41 (10) 4715-4718; DOI: https://doi.org/10.21873/anticanres.15285
You have access
Successful Stabilization of Symptomatic Bone Marrow Metastasis Two Times in a Breast Cancer Patient
HIDEKO AKAGI, AKIHIKO SHIMADA, KENKO CHIN and HIDEHARU DOMOTO

Anticancer Research June 2021, 41 (6) 3139-3144; DOI: https://doi.org/10.21873/anticanres.15099
You have access
Bioreductive Activation of Antitumour Drugs, Doxorubicin and Pirarubicin, Does Not Affect Their Ability to Induce Apoptosis of Sensitive and Multidrug Resistant Leukaemia HL60 Cells
DOROTA KOSTRZEWA-NOWAK and JOLANTA TARASIUK

Anticancer Research March 2021, 41 (3) 1429-1438; DOI: https://doi.org/10.21873/anticanres.14900

Main menu

User menu

Search

doxorubicin

Pages